Diphenhydramine for Sleep: What the Evidence Shows

Verdict: Weak for ongoing use. Short-term sedative effect is real but tolerance develops within days. AASM recommends against it for chronic insomnia. Significant concerns for older adults.

The claim: diphenhydramine helps you sleep. It does, for a few nights. The problem is what happens after that, and what else it does while it is working. This is the most widely used OTC sleep aid in the United States, and the evidence base does not support the way most people use it.

The claim inventory

The product claim is simple and pharmacologically accurate in the short term: “helps you fall asleep.” The products are branded for this purpose: ZzzQuil, Simply Sleep, Unisom SleepTabs (the diphenhydramine version), and the PM variants of pain relievers. The claim is true for a few nights. What the label does not tell you is that the effect diminishes within days of regular use, that the drug has significant side effects beyond sedation, and that the primary medical guideline for insomnia recommends against it.

The mechanism

Diphenhydramine is a first-generation antihistamine that readily crosses the blood-brain barrier. Histamine is one of the brain’s primary wake-promoting neurotransmitters, part of the ascending arousal system that keeps you conscious during the day. Blocking H1 histamine receptors reduces this wake signal and produces sedation. This is not a designed sleep mechanism. It is a pharmacological side effect that found a market.

Diphenhydramine was developed as an allergy medication in the 1940s. The drowsiness it caused in allergy patients was recognized as commercially useful, and it was repackaged as a sleep aid. The molecule has not changed. The same anticholinergic effects that produce dry mouth during allergy treatment produce dry mouth, urinary retention, constipation, blurred vision, and cognitive impairment during sleep use. These are not side effects in the colloquial sense of rare, unexpected reactions. They are predictable pharmacological consequences of the drug’s receptor binding profile.

Beyond histamine, diphenhydramine blocks muscarinic acetylcholine receptors (anticholinergic activity), which is responsible for most of the side effects. Acetylcholine plays roles in memory, attention, and autonomic function. Blocking it produces the cognitive fog, dry mouth, and GI effects that users report.

What the evidence shows

Diphenhydramine does reduce sleep onset latency in the short term. This is pharmacologically expected from a centrally acting antihistamine with strong H1 binding. The more clinically important finding is how quickly that effect fades.

Richardson et al. demonstrated that tolerance to the sedative effects of diphenhydramine develops within 3-4 days of regular use [2]. The body upregulates histamine receptors in response to chronic blockade, restoring wake-promoting histamine signaling to baseline. By day four, the drug is no longer producing the sedation it produced on day one. Most people who take diphenhydramine nightly for weeks or months are taking a drug that has lost most of its sedative effect and retained its anticholinergic side effects.

This tolerance pattern is well-characterized for first-generation antihistamines. It is one of the primary reasons the AASM guideline recommends against diphenhydramine for chronic insomnia: the benefit is short-lived, but people continue taking the drug long after the benefit has faded.

What the guidelines say

The AASM clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults specifically recommends against diphenhydramine [1]. This is not a neutral “insufficient evidence” position. It is not a “more research needed” position. It is an explicit recommendation against use, based on the risk-benefit assessment: rapid tolerance development, anticholinergic side effects, no evidence for sustained benefit, and the availability of better-supported alternatives.

The guideline’s wording distinguishes this from supplements where the verdict is ambiguous. For diphenhydramine, the AASM reviewed the available evidence and concluded that the risks outweigh the benefits for chronic use.

The older adult concern

The American Geriatrics Society Beers Criteria lists diphenhydramine as potentially inappropriate for adults over 65 [3]. This is significant because older adults are the demographic most likely to have chronic insomnia and most likely to reach for OTC sleep aids.

In older adults, anticholinergic effects are more pronounced and more dangerous: increased fall risk due to sedation and postural hypotension, confusion and delirium, urinary retention (which can lead to urinary tract infections), and worsening of existing cognitive impairment. The Beers Criteria places diphenhydramine on its “avoid” list for this population.

Gray et al. conducted a prospective cohort study following 3,434 adults aged 65 and older and found that higher cumulative anticholinergic use, including diphenhydramine, was associated with increased risk of incident dementia [4]. The dose-response relationship was significant: the more cumulative anticholinergic exposure, the higher the dementia risk. This is an observational finding, not proof of causation. Confounding factors exist. But the association is consistent across multiple cohort studies and adds to the safety concern for long-term use.

The repackaging phenomenon

One of the more notable aspects of diphenhydramine’s market presence is the number of products that contain the exact same molecule at the exact same dose, marketed under different brand names for different purposes. Benadryl is diphenhydramine 25mg marketed as an allergy medication. ZzzQuil is diphenhydramine 25-50mg marketed as a sleep aid. Unisom SleepTabs are diphenhydramine 25mg marketed as a sleep aid. The PM versions of pain relievers (Advil PM, Tylenol PM) contain diphenhydramine 25mg alongside the pain reliever. In each case, the sedation comes from the same drug working through the same receptor.

This matters because a consumer who switches from ZzzQuil to “a different sleep product” may purchase Unisom SleepTabs and be taking the same medication. The branding creates an illusion of choice that does not exist pharmacologically. It also obscures the total diphenhydramine exposure for a person who might take Benadryl for allergies during the day and a PM pain reliever for sleep at night, inadvertently doubling their anticholinergic load.

The market structure also reveals something about how the pharmaceutical industry treats sleep. No company has invested in the large, long-term trials that would be needed to properly characterize diphenhydramine for chronic insomnia, because the molecule is off-patent, cheap, and already selling well. The commercial incentive to generate evidence is absent: the product sells without it.

The persistence problem

Morin et al.’s population-based longitudinal study found that OTC sleep aid use was associated with persistent rather than resolving insomnia over three years of follow-up [5]. People who used OTC sleep aids were more likely to still have insomnia at the end of the study period than people who did not. This does not prove that the medication causes insomnia to persist. But it suggests that reaching for OTC antihistamines does not put people on a path toward resolution.

The mechanism for this association may be behavioral: diphenhydramine addresses the symptom (wakefulness) without addressing the cause (behavioral and cognitive factors maintaining insomnia). People who take a pill to sleep do not change their sleep habits. They continue going to bed too early, lying in bed awake, napping during the day, and associating the bed with wakefulness. The pill masks the problem briefly, tolerance removes the mask, and the underlying insomnia is unchanged.

How it compares to CBT-I

The contrast is sharp. CBT-I addresses the factors that maintain insomnia: excessive time in bed, conditioned arousal, clock-watching, catastrophizing. Its effects are durable, with meta-analyses showing sustained improvement at two-year follow-up. Diphenhydramine addresses the symptom for a few nights and then stops working. CBT-I requires effort and active engagement over several weeks. Diphenhydramine requires a trip to the drugstore. The convenience gap explains the usage gap. The evidence gap runs in the opposite direction.

The irony is that diphenhydramine may actually make CBT-I harder to start. A person who has been using diphenhydramine nightly and attempts to stop will experience rebound insomnia from discontinuation. This worsened sleep gets attributed to the underlying insomnia rather than to withdrawal, reinforcing the belief that the medication was necessary and that the insomnia is untreatable without it. Breaking this cycle often requires a structured taper guided by a clinician, followed by behavioral intervention. The medication that was supposed to bridge a few bad nights can become an obstacle to the treatment that would actually resolve the problem.

What the label does not tell you

The packaging of OTC diphenhydramine sleep aids typically warns not to use the product for more than two weeks without consulting a doctor. This warning, buried in small print, effectively acknowledges the tolerance problem. Most consumers do not read the warning, and most who do read it do not follow it. The product is available without prescription, without pharmacist consultation in most stores, and without any mechanism to limit the duration of use. The two-week warning exists. The product design ensures it is ignored.

The bottom line

Diphenhydramine produces real sedation for a few nights. Tolerance develops within days. The AASM explicitly recommends against it for chronic insomnia. Anticholinergic side effects are a genuine concern, particularly for older adults where the Beers Criteria flags it as potentially inappropriate. It is the most widely used OTC sleep aid in the US, and the evidence base does not support how it is commonly used. A drug that stops working by day four but keeps producing side effects is a poor tool for a condition that lasts months or years.

If you’re struggling with sleep regularly, speak with a GP or pharmacist before adding supplements or medications. For persistent insomnia, AASM guidelines recommend CBT-I as the first-line treatment. The American Academy of Sleep Medicine has a provider finder at sleepeducation.org.